<DOC>
	<DOC>NCT00389675</DOC>
	<brief_summary>This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan (optimized dose) as compared to an active control, administered orally.</brief_summary>
	<brief_title>DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<mesh_term>LU 135252</mesh_term>
	<criteria>SELECTED INCLUSION CRITERIA: 1. Subjects must be competent to provide written informed consent; 2. Subjects must have completed the Maintenance Period of the DAR312 study. SELECTED EXCLUSION CRITERIA: 1. Subjects who discontinue treatment with study drug prior to the end of the Maintenance Period in DAR312 due to a study drugrelated AE; 2. Subjects who experience a study drugrelated serious adverse event (SAE) during the DAR312 study.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>